Previous 10 | Next 10 |
home / stock / rlftf / rlftf news
GENEVA, SWITZERLAND / ACCESSWIRE / November 4, 2020 / RELIEF THERAPEUTICS Holding AG (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead compound RLF-100 TM (aviptadil) in advanced clinical development to treat severe COVID-19 patients, today an...
Relief Therapeutics (RLFTF) and NeuroRx announce topline results from 45 patients assessed in an open-label prospective study where 21 patients admitted to ICU with critical COVID-19 and respiratory failure were treated with RLF-100 (Aviptadil) compared to 24 control patients treate...
NeuroRx and Relief announce topline efficacy data from patients treated with RLF-100™ (aviptadil) under the U.S. FDA Expanded Access Protocol authorization for respiratory failure related to critical COVID-19 - RLF-100™ therapy associated with a 9-fold increased pr...
Relief Therapeutics (RLFTF) has appointed Jack Weinstein as Chief Financial Officer ((CFO)) and Treasurer, effective immediately.Mr. Weinstein brings over 40 years of wide-ranging expertise. Before joining Relief, he served as Managing Director and Head of Healthcare Investment Banking at Ava...
Relief Therapeutics (RLFTF) and NeuroRx have established supply chain agreements and ordered sufficient drug substance (RLF-100) to prepare to treat 1M patients with COVID-19, should the pandemic continue. Relief and NeuroRx have now contracted with Nephron Pharmaceuticals to manufacture comm...
NeuroRx and Relief Therapeutics Establish Supply and Distribution Agreements for RLF-100™ (aviptadil) Development partners establish supply chain agreements and order sufficient drug substance to treat 1 million patients PR Newswire GENEVA and RADNOR, Pa., Sept. 3...
Relief Announces Capital Increase from its Final Tranche of the Share Subscription Facility with GEM GENEVA, SWITZERLAND / ACCESSWIRE / September 28, 2020 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF) (" Relief " or the " Company "), a biopharmaceutical company with its lead ...
NeuroRx has submitted a request for an Emergency Use Authorization ((EUA)) with the FDA for the use of RLF-100 aviptadil in patients who are receiving intensive care and have exhausted all approved treatments.RLF-100 is being developed by NeuroRx as part of a global partnership with Reli...
NeuroRx submits request for Emergency Use Authorization for RLF-100™ (aviptadil) in the treatment of patients with Critical COVID-19 and Respiratory Failure who have exhausted approved therapy Emergency Use Authorization request targets the same population as is currently...
FinancialBuzz.com News Commentary New York, NY (9/22/2020) – Due to increasing awareness amongst consumers on hygiene and preventive healthcare, the global surface disinfectant market is anticipated to grow significantly in the coming years. The current pandemic has caused major ...
News, Short Squeeze, Breakout and More Instantly...
Mondobiotech Holding AG Basel Company Name:
RLFTF Stock Symbol:
OTCMKTS Market:
GENEVA, SWITZERLAND / ACCESSWIRE / May 8, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select rare diseases, today announced the formation of its ne...
GENEVA, SWITZARLAND / ACCESSWIRE / April 30, 2024 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today published its Annual Repo...
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call p...